Entries |
Document | Title | Date |
20100286047 | USE OF VWF STABILIZED FVIII PREPARATIONS AND OF VWF PREPARATIONS WITHOUT FVIII FOR EXTRAVASCULAR ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS - The present invention relates to the use of von Willebrand Factor (VWF) preparations or of a VWF preparation in combination with coagulation Factor VIII (FVIII) for extravascular administration in the therapy and prophylactic treatment of bleeding disorders. | 11-11-2010 |
20100323966 | FVIII Peptides and Their Use in Tolerising Haemophiliacs - The present invention provides a peptide comprising a core residue sequence derivable from human FVIII which peptide is capable of binding to an MHC class II molecule without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia. | 12-23-2010 |
20110003752 | New Blood Coagulation Factor Inhibitors - The invention relates to novel compounds with formula (I) X | 01-06-2011 |
20110021430 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 01-27-2011 |
20110059894 | Factor VII Polypeptides for Preventing Formation of Inhibitors in Subjects with Haemophilia - The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide. | 03-10-2011 |
20110077203 | NUCLEIC ACID AND AMINO ACID SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE - Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A. | 03-31-2011 |
20110112022 | Factor VIII Muteins with Reduced Immonugenicity - The invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia. | 05-12-2011 |
20110112023 | VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES - The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. | 05-12-2011 |
20110112024 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 05-12-2011 |
20110112025 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 05-12-2011 |
20110112026 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 05-12-2011 |
20110112027 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 05-12-2011 |
20110112028 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 05-12-2011 |
20110118188 | FACTOR VIII POLYPEPTIDE HAVING FACTOR VIII:C ACTIVITY - Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same. | 05-19-2011 |
20110124565 | Modified Coagulation Factor VIII With Enhanced Stability and Its Derivatives - The present invention relates to modified nucleic acid sequences coding for coagulation factors, in particular human Factor VIII and their derivatives with improved stability, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises modified DNA sequences. | 05-26-2011 |
20110144025 | Methods of Reducing Hemorrhage Due to Surgical Procedure - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 06-16-2011 |
20110172156 | METHODS AND COMPOSITIONS FOR TREATING BLEEDING DISORDERS - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described. | 07-14-2011 |
20110178019 | NEW PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VIII - A histidine-free composition comprising:
| 07-21-2011 |
20110183907 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences. | 07-28-2011 |
20110237512 | Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides - Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described. | 09-29-2011 |
20110275570 | PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OF A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME - A method of treating a patient suffering from Haemophilia A and/or Von Willebrand's disease involves administering the patient a concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of up to 12 IU VWF:RCo/ml and a VWF/Factor VIII ratio of 0.4 or more, and nanofiltering that starting solution through a filter of pore size of about 35 nm or smaller. The resulting VWF retains high molecular weight multimers. | 11-10-2011 |
20110306551 | Modification of Factor VIII - A Factor VIII derivative of formula (I): wherein: B represents C | 12-15-2011 |
20120028900 | METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS - Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein. | 02-02-2012 |
20120035110 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE - Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH | 02-09-2012 |
20120065136 | RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE - The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed. | 03-15-2012 |
20120083446 | NOVEL ALBUMIN-FREE FACTOR VIII FORMULATIONS - An albumin-free Factor VIII formulation comprising, 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent. | 04-05-2012 |
20120129777 | Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides - Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described. | 05-24-2012 |
20120142593 | Factor VIII Variants and Methods of Use - A Factor VIII fusion protein or a Factor VIII fusion heterodimer comprising Factor VIII in which an amino acid sequence of a modulator is present in the B-domain, or an amino acid sequence of a modulator replaces some or all of the amino acid sequence of the B-domain is disclosed. Nucleic acids encoding the inventive fusion proteins and fusion heterodimers are also disclosed, as are methods for producing the fusion proteins and fusion heterodimers, pharmaceutical compositions, and methods of treating deficiencies in coagulation with the inventive fusion molecules. | 06-07-2012 |
20120142594 | Von Willebrand Factor- and Factor VIII-Polymer Conjugates Having a Releasable Linkage - The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided. | 06-07-2012 |
20120178691 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 07-12-2012 |
20120178692 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient. | 07-12-2012 |
20120190623 | Inactivation Resistant Factor VIII - The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated, an amino acid sequence spacer is inserted between the A2- and A3-domains. Methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia, are also provided. | 07-26-2012 |
20120225819 | STABLE FORMULATION OF FACTOR VIII - The invention relates inter alia to a composition which is storage-stable at 25° C. for a minimum of 18 weeks comprising a therapeutically effective amount of Factor VIII and an aqueous medium having a Factor VIII potency after 18 weeks of storage at 25° C. of at least 90% of the Factor VIII potency of a Control Composition. | 09-06-2012 |
20120270788 | Method of Administering Porcine B-Domainless fVIII - The present invention provides a method of administering porcine B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant B-domainless porcine fVIII, termed OBI-1, has greater bioavailability compared to the natural porcine fVIII partially purified from porcine plasma, termed HYATE:C. Therefore, the inventive method employs lower unit doses of OBI-1, including, alternatively, omission of antibody-neutralizing dosage, or has longer intervals between the administration, compared to HYATE:C, to provide equivalent protection in patients having fVIII deficiency. The invention further provides pharmaceutical compositions and kits containing OBI-1 in combination with a pharmaceutically acceptable carrier, that are useful for treating patients in need of fVIII more effectively. | 10-25-2012 |
20120289468 | VON WILLEBRAND FACTOR (VWF)-CONTAINING PREPARATIONS, AND METHODS, KITS, AND USES RELATED THERETO - The present invention relates to methods, compositions and kits for preparing FVIII and employing same. Also provided are vWF polypeptides and nucleic acid molecules encoding same. | 11-15-2012 |
20120316116 | TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF - The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII. | 12-13-2012 |
20120322738 | CONJUGATED FVIII VARIANTS - The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof. | 12-20-2012 |
20130005656 | Modified Factor VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 01-03-2013 |
20130005657 | SYNERGISTIC THERAPEUTIC USE OF PROTHROMBIN COMPLEX CONCENTRATES WITH FVlll CONCENTRATES - The field of the invention is the treatment of acquired bleeding, a clinical condition associated with severe traumatic, peri- or post-operative bleeding. A novel treatment is proposed in which synergistic pro-coagulatory properties of Prothrombin Complex Concentrates (PCC) together with medicaments comprising FVIII and/or vWF are exploited. | 01-03-2013 |
20130012442 | VON WILLEBRAND FACTOR- AND FACTOR VIII-POLYMER CONJUGATES HAVING A RELEASABLE LINKAGE - The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided. | 01-10-2013 |
20130017997 | Factor VIII Compositions and Methods of Making and Using Same - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 01-17-2013 |
20130035288 | Resorption Enhancers As Additives To Improve The Oral Formulation Of Non-Anticoagulant Sulfated Polysaccharides - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described. | 02-07-2013 |
20130040888 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 02-14-2013 |
20130040889 | Factor VIII Fusion Protein - The present invention relates to modified coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules fused to a polypeptide such as e.g. an antibody binding protein or a Fc domain. | 02-14-2013 |
20130072434 | INACTIVATION RESISTANT FACTOR VIII - The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences may encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences also may encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated, an amino acid sequence spacer is inserted between the A2- and A3-domains. Provided herein are methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia. | 03-21-2013 |
20130085110 | RECOMBINANT FACTOR VIII HAVING INCREASED STABILITY - The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule. | 04-04-2013 |
20130116182 | Factor VIII B Cell Epitope Variants Having Reduced Immunogenicity - Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII. | 05-09-2013 |
20130123181 | Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity - Provided herein are methods and compositions for preventing or reducing an initial immune response to factor VIII in patients suffering from hemophilia A, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor VIII. | 05-16-2013 |
20130137638 | CONJUGATED FACTOR VIII MOLECULES - The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules. | 05-30-2013 |
20130143818 | Factor VIII Glycoforms - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 06-06-2013 |
20130150302 | CONJUGATED BLOOD COAGULATION FACTOR VIII - The present invention provides a biocompatible polymer conjugated to FVIII via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIII, and pharmaceutical compositions comprising such conjugated forms of FVIII. | 06-13-2013 |
20130184216 | NOVEL ALBUMIN-FREE FACTOR VIII FORMULATIONS - A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent. | 07-18-2013 |
20130190242 | Polymer-Von Willebrand Factor-Conjugates - The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF. | 07-25-2013 |
20130267468 | FACTOR VIII GLYCOFORMS - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 10-10-2013 |
20130274194 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof - The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 10-17-2013 |
20130296243 | MODIFIED RECOMBINANT FACTOR VIII AND VON WILLEBRAND FACTOR AND METHODS OF USE - The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention. | 11-07-2013 |
20130296244 | VARIANT OF ANTIHEMOPHILIC FACTOR VIII HAVING INCREASED SPECIFIC ACTIVITY - The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products. | 11-07-2013 |
20140018297 | COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA - The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound. | 01-16-2014 |
20140057848 | FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE - The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake. | 02-27-2014 |
20140128325 | VON WILLEBRAND FACTOR OR FACTOR VIII AND VON WILLEBRAND FACTOR FOR THE TREATMENT OF COAGULOPATHY INDUCED BY INHIBITORS OF THROMBOCYTES - The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. | 05-08-2014 |
20140221290 | STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS - A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa. | 08-07-2014 |
20140249086 | Method for Improving the Stability of Purified Factor VIII After Reconstitution - The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection. | 09-04-2014 |
20140274902 | RECOMBINANT FVIII FORMULATIONS - Provided are liquid and lyophilized rFVIII formulations, including full-length rFVIII (FL-rFVIII) formulations, B-domain deleted rFVIII (BDD-rFVIII) formulations, and BDD-rFVIII mutant (BDD-rVIII mutant) formulations. Also provided are liquid and lyophilized PEGylated rFVIII (PEG-rFVIII) formulations, including PEGylated full-length rFVIII (PEG-FL-rFVIII) formulations, PEGylated B-domain deleted rFVIII (PEG-BDD-rFVIII) formulations, and PEGylated BDD-rFVIII mutant (PEG-BDD-rFVIII mutant) formulations. | 09-18-2014 |
20140274903 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST - This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes. | 09-18-2014 |
20140315815 | USE OF SULFATED GLYCOSAMINOGLYCANS FOR IMPROVING THE BIOAVAILABILITY OF FACTOR VIII - The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan. | 10-23-2014 |
20140357564 | Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity - The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation. | 12-04-2014 |
20140357565 | METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS - Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-a (CHEF1) promoter, which may be used in the methods provided herein. | 12-04-2014 |
20150025010 | NOVEL ALBUMIN-FREE FACTOR VIII FORMULATIONS - A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent. | 01-22-2015 |
20150038421 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 02-05-2015 |
20150038422 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE - Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient. | 02-05-2015 |
20150045303 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 02-12-2015 |
20150080309 | Compounds Suitable for Treatment of Haemophilia - The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases. | 03-19-2015 |
20150087593 | COAGULATION FACTOR VIII WITH REDUCED IMMUNOGENICITY - The invention describes factor VIII molecules with reduced capacity to elicit activation of NKT cells for use in the treatment of congenital and/or acquired haemophilia A and in bleeding disorders. Said factor VIII molecule is obtainable by:
| 03-26-2015 |
20150126449 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use - The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis. | 05-07-2015 |
20150306234 | MUTEINS OF CLOTTING FACTOR Vlll - The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers. | 10-29-2015 |
20150337028 | Double Mutant Coagulation Factor VIII and Methods Thereof - A double mutant B-domain deleted Factor VIII gene having mutations at Phe309Ser and Asp519Val, respectively, is disclosed for use in the field of haemophilia therapeutics. The disclosure a double mutant B-domain deleted Factor VIII protein having mutations at Phe309Ser and Asp519Val respectively, is also disclosed, as well as methods of producing the same. The B-domain deleted Factor VIII protein having mutations at Phe309Ser and Asp519Val shows enhanced activity and stability and therefore is used in the management of haemophilia. | 11-26-2015 |
20150353625 | VARIANT OF ANTIHEMOPHILIC FACTOR VIII HAVING INCREASED SPECIFIC ACTIVITY - The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor VIII having increased specific activity in comparison to known factor VIII products. | 12-10-2015 |
20160002314 | FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE - The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake. | 01-07-2016 |
20160030524 | RECOMBINANT FACTOR VIII FORMULATIONS - Provided are liquid and lyophilized recombinant Factor VIII formulations, including formulations for polymer-conjugated FVIII such as PEGylated Factor VIII. | 02-04-2016 |
20160031968 | VARIANT FACTOR VIII POLYPEPTIDES AND METHODS OF THEIR PRODUCTION AND USE - This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids. | 02-04-2016 |
20160051633 | METHODS OF TREATING HEMOPHILIA IN PATIENTS HAVING DEVELOPED INHIBITORY ANTIBODIES - This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. | 02-25-2016 |
20160115219 | FACTOR VIII GLYCOFORMS - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 04-28-2016 |
20160120953 | Factor VIII Conjugates - The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia. | 05-05-2016 |
20160120954 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 05-05-2016 |
20160184403 | TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF - The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII. | 06-30-2016 |
20160199455 | Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof | 07-14-2016 |
20160200794 | COMPLEX | 07-14-2016 |
20160251408 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | 09-01-2016 |
20160376344 | FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions. | 12-29-2016 |
20190142973 | ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A | 05-16-2019 |
20190144524 | FACTOR VIII VARIANTS, NUCLEIC ACID SEQUENCES, AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS | 05-16-2019 |